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BACKGROUND—Multiple laboratory tests are used in the diagnosis and management of
patients with diabetes mellitus. The quality of the scientiﬁc evidence supporting the use of these
assays varies substantially.
APPROACH—An expert committee compiled evidence-based recommendations for the use
of laboratory analysis in patients with diabetes. A new system was developed to grade the overall
quality of the evidence and the strength of the recommendations. A draft of the guidelines was
postedontheInternet,andthedocumentwasmodiﬁedinresponsetocomments.Theguidelines
werereviewedbythejointEvidence-BasedLaboratoryMedicineCommitteeoftheAACCandthe
NationalAcademy of Clinical Biochemistryand wereaccepted afterrevisions bythe Professional
Practice Committee and subsequent approval by the Executive Committee of the American
Diabetes Association.
CONTENT—Inadditiontothelong-standingcriteriabasedonmeasurementofvenousplasma
glucose, diabetes can be diagnosed by demonstrating increased hemoglobin A1c (HbA1c) con-
centrations in the blood. Monitoring of glycemic control is performed by the patients measuring
theirownplasmaorbloodglucosewithmetersandbylaboratoryanalysisofHbA1c.Thepotential
roles of noninvasive glucose monitoring, genetic testing, and measurement of autoantibodies,
urine albumin, insulin, proinsulin, C-peptide, and other analytes are addressed.
SUMMARY—The guidelines provide speciﬁc recommendations based on published data or
derived from expert consensus. Several analytes are found to have minimal clinical value at the
present time, and measurement of them is not recommended.
Diabetes Care 34:1419–1423, 2011
D
iabetes mellitus is a group of met-
abolic disorders of carbohydrate
metabolism in which glucose is
underutilized and overproduced, leading
to hyperglycemia. Diabetes is a common
disease. The current worldwide preva-
lence is estimated to be approximately
250310
6andisexpectedtoreach3803
10
6 by 2025 (1). The most recent data,
derived from the 2005–2006 National
Health and Nutrition Examination Sur-
vey, show a prevalence of diabetes in the
U.S.inpersons$20yearsofageof12.9%
(equivalent to approximately 40 3 10
6
people) (2), 40% (approximately 16 3
10
6)ofwhomareundiagnosed.Theprev-
alence of diabetes has also increased in
other parts of the world. Recent estimates
suggest 110 x 10
6 diabetic individuals in
Asia in 2007 (3), but the true number is
likely to be substantially greater, because
China alone was thought to have 92.4 3
10
6 adults with diabetes in 2008 (4).
The worldwide costs of diabetes in 2007
were approximately $232 billion and are
likely to be $302 billion by 2025 (1). The
mean annual per capita healthcare costs
for an individual with diabetes are ap-
proximately 2.3-fold higher than those
for individuals who do not have diabetes
(5). The high costs of diabetes are attrib-
utable to care for both acute conditions
(such as hypoglycemia and ketoacidosis)
and debilitating chronic microvascular
andmacrovascularcomplications(6).To-
gether, they make diabetes the fourth
most common cause of death in the de-
veloped world (7).
The National Academy of Clinical
Biochemistry (NACB) issued its “Guide-
lines and Recommendations for Labora-
tory Analysis in the Diagnosis and
Management of Diabetes Mellitus” in
2002 (8). These recommendations were
reviewedandupdatedbyamultidisciplin-
aryguidelineteamusinganevidence-based
approach, especially in key areas in which
new evidence has emerged since the pre-
vious edition. The guideline committee,
whose membership was mostly from the
U.S., included clinical, laboratory, and
ccccccccccccccccccccccccccccccccccccccccccccccccc
From the
1Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland; the
2De-
partment of Chemistry, University of Iowa, Iowa City, Iowa; the
3Department of Medicine, Hypertensive
DiseaseUnit, Sectionof Endocrinology, Diabetes and Metabolism, University of Chicago,Chicago,Illinois;
the
4Department of Pathology, University of Virginia Medical School, Charlottesville, Virginia; the
5ScreeningandTestEvaluationProgram,SchoolofPublicHealth,UniversityofSydney,SEALSDepartment
of Clinical Chemistry, Prince of Wales Hospital, Sydney, Australia; the
6American Diabetes Association,
Alexandria, Virginia; the
7Department of Clinical Sciences, Lund University/CRC, Skane University Hos-
pital Malmö, Malmö, Sweden; the
8Division of Endocrinology, Northwestern University, The Feinberg
School of Medicine, Chicago, Illinois; and the
9Massachusetts General Hospital and Harvard Medical
School, Diabetes Center, Boston, Massachusetts.
Corresponding author: David B. Sacks, sacksdb@mail.nih.gov.
Received 11 February 2011 and accepted 25 February 2011.
DOI: 10.2337/dc11-9997
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.
2337/dc11-9997/-/DC1.
This article is simultaneously published in Clinical Chemistry and Diabetes Care, under joint copyright, and by
the National Academy of Clinical Biochemistry.
© 2011 by the American Diabetes Association and the American Association for Clinical Chemistry. Readers
may use this article as long as the work is properly cited, the use is educational and not for proﬁt, and the
work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
See accompanying article, p. e61.
care.diabetesjournals.org DIABETES CARE, VOLUME 34, JUNE 2011 1419
Reviews/Commentaries/ADA Statements
POSITION STATEMENT EXECUTIVE SUMMARYevidence-based guideline methodology
experts. Members of the guideline com-
mittee have disclosed any ﬁnancial, per-
sonal, or professional relationships that
might constitute conﬂicts of interest
with this guideline and have received no
directfundingrelatedtothedevelopment
of the recommendations. The perspec-
tives and views of various international
and national organizations, as well as
otherpotential stakeholders(e.g.,health-
care providers, patients, policy makers,
regulatory bodies, health insurance com-
panies, researchers, and industry) were
taken into account during the public-
consultation process. A new system was
developed to grade both the overall qual-
ity of the evidence (Table 1) and the
strength of recommendations (Table 2).
Theprocessofupdatingguidelinerecom-
mendations followed the standard oper-
ating procedures for issuing NACB
laboratory medicine practice guidelines,
and the key steps are detailed in the
guideline and accompanying supple-
ments available in the Supplementary
Data that accompanies the online version
of this report.
This guideline focuses on the practi-
cal aspects of care in order to assist with
decisions related to the use or interpreta-
tion of laboratory tests while screening,
diagnosing, or monitoring patients with
diabetes. It covers the rationale and pre-
analytical, analytical, postanalytical, and,
where applicable, emerging consider-
ations, the last of which alert the reader
to ongoing studies and potential future
aspects relevant to each analyte. The
recommendations intend to supplement
the American Diabetes Association guide-
lines and thus do not address any issues
related to the clinical management of
patients. The full version of this guideline
and its accompanying supplements are
available in the Supplementary Data that
accompanies the online version of this
report. Key recommendations are sum-
marized below.
These recommendations primarily
target laboratory professionals, general
practitioners, physicians, nurses, and
other healthcare practitioners involved
i nt h ec a r eo fd i a b e t i cp a t i e n t s .T h e
guidelines can be used by patients
(where relevant, e.g., self-monitoring of
blood glucose [SMBG]), policy makers,
and payers for healthcare, as well as by
researchers and manufacturers. Al-
though the recommendations were de-
veloped for national and international
use and were intended to be generic,
certain recommendations may not reﬂect
views that are universally held or may
have limited applicability in healthcare
settings with differing organizational,
cultural, and economic backgrounds.
The guideline committee therefore advises
users to adapt recommendations to local
settings.
The next review of this guideline is
plannedin5years,unlesssubstantialnew
evidence emerges earlier for high-priority
areas in the laboratory management of
patients with diabetes mellitus.
RECOMMENDATIONS—Capital
letters denote the grade of recommenda-
tions, and categories in brackets refer to
the quality of the underlying body of
evidence supporting each recommenda-
tion. The grading system is described in
Tables 1 and 2.
1. Glucose
a. When glucose is used to establish the
diagnosis of diabetes, it should be mea-
sured in venous plasma. A( h i g h )
b. When glucose is used for screening
of high-risk individuals, it should be
measured in venous plasma. B( m o d e r -
ate)
c. Plasma glucose should be measured in
an accredited laboratory when used for
diagnosis of or screening for diabetes.
GPP (good practice point)
d. Outcome studies are needed to de-
termine the effectiveness of screening.
C( m o d e r a t e )
e. Routine measurement of plasma glu-
cose concentrations in an accredited
laboratory is not recommended as the
primary means of monitoring or evaluat-
ing therapy in individuals with diabetes.
B (low)
f. Blood for fasting plasma glucose anal-
ysis should be drawn in the morning after
the individual has fasted overnight (at
least 8 h). B( l o w )
g. To minimize glycolysis, one should
place the sample tube immediately in an
ice–water slurry, and plasma should be
separated from the cells within 30 min. If
thatcannotbeachieved,atubecontaining
a rapidly effective glycolysis inhibitor,
such as citrate buffer, should be used for
collecting the sample. Tubes with only
enolase inhibitors, such as sodium ﬂuo-
ride, should not be relied on to prevent
glycolysis. B (moderate)
h. On the basis of biological variation,
glucose measurement should have an an-
alyticalimprecision #2.9%, abias #2.2%,
and a total error #6.9%. To avoid mis-
classiﬁcation of patients, the goal for glu-
cose analysis should be to minimize total
analytical error, and methods should be
without measurable bias. B (low)
2. Glucose meters
a. There are insufﬁcient published data to
support a role for portable meters and
skin-prick (ﬁnger-stick) blood samples in
thediagnosisofdiabetesorforpopulation
screening. C( m o d e r a t e )
b. The imprecision of the results, coupled
with the substantial differences among
meters,precludestheuseofglucosemeters
from the diagnosis of diabetes and limits
their usefulness in screening for diabetes.
A( m o d e r a t e )
Table 1—Rating scale for the quality of evidence
High: Further research is very unlikely to change our conﬁdence in the estimate of effect. The body of evidence comes from high-level individual
studies that are sufﬁciently powered and provide precise, consistent, and directly applicable results in a relevant population.
Moderate: Further research is likely to have an important impact on our conﬁdence in the estimate of effect and may change the estimate and the
recommendation. The body of evidence comes from high-/moderate-level individual studies that are sufﬁcient to determine effects, but the
strengthoftheevidenceislimitedbythenumber,quality,orconsistencyoftheincludedstudies;generalizabilityofresultstoroutinepractice;or
indirect nature of the evidence.
Low: Further research is very likely to have an important impact on our conﬁdence in the estimate of effect and is likely to change the estimate and
the recommendation. The body of evidence is of low level and comes from studies with serious design ﬂaws, or evidence is indirect.
Very low: Any estimate of effect is very uncertain. Recommendation may change when higher-quality evidence becomes available. Evidence is
insufﬁcient to assess the effects on health outcomes because of limited number or power of studies, important ﬂaws in their design or conduct,
gaps in the chain of evidence, or lack of information.
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Position Statement Executive Summaryc. SMBG is recommended for all insulin-
treated patients with diabetes. A (high)
d. In patients with type 2 diabetes treated
with dietandoralagents,SMBGmayhelp
achieve better control, particularly when
therapy is initiated or changed. Data are
insufﬁcient, however, to claim an associ-
ated improvement of health outcomes.
The role of SMBG in patients with stable
type 2 diabetes controlled by diet alone is
not known. C( h i g h )
e. Patients should be instructed in the
correct use of glucose meters, includ-
ing quality control. Comparison between
SMBG and concurrent laboratory glucose
analysis should be performed at regular
intervals to evaluate the performance of the
metersinthepatient’shands.B(moderate)
f. Multiple performance goals for portable
glucose meters have been proposed. These
targets vary widely and are highly contro-
versial. Manufacturers should work to im-
prove the imprecision of current meters,
with an intermediate goal of limiting total
error for 95% of samples to #15% at
glucose concentrations $5.6 mmol/L (100
mg/dL) andto,0.8mmol/L(15mg/dL)at
glucose concentrations ,5.6 mmol/L (100
mg/dL). Lower total error would be desir-
able and may prove necessary in tight
glucose-control protocols and for avoiding
hypoglycemia in all settings. C( l o w )
g. Meters should measure and report
plasma glucose concentrations to facilitate
comparison with assays performed in ac-
credited laboratories. GPP
h. Studies are needed to determine the
analyticalgoals(qualityspeciﬁcations)for
glucose meters in SMBG and in intensive
care units. C (moderate)
i. Recommendations for future research:
Important end points in studies of SMBG
should include, at a minimum, hemoglo-
bin A1c (HbA1c) and frequency of hypo-
glycemic episodes to ascertain whether
improvedmetersenablepatientstoachieve
better glucose control. For studies ofmeter
use in intensive or critical care, important
end points include mean blood glucose,
frequency of hypoglycemia, and variation
of glucose control. Ideally, outcomes (e.g.,
long-term complications) should also be
examined. GPP
3. Continuous minimally invasive
glucose analyses
a. Real-time continuous glucose moni-
toring (CGM) in conjunction with in-
tensive insulin regimens can be a useful
tool to lower HbA1c in selected adults
Table 2—Grading the strength of recommendations
A. The NACB strongly recommends adoption
Strong recommendations for adoption are made when
c There is high-quality evidence and strong or very strong agreement of experts that the intervention improves important health outcomes
and that beneﬁts substantially outweigh harms; or
c There is moderate-quality evidence and strong or very strong agreement of experts that the intervention improves important health
outcomes and that beneﬁts substantially outweigh harms.
Strong recommendations against adoption are made when
c There is high-quality evidence and strong or very strong agreement of experts that the intervention is ineffective or that beneﬁts are closely
balanced with harms, or that harms clearly outweigh beneﬁts; or
c There is moderate-quality evidence and strong or very strong agreement of experts that the intervention is ineffective or that beneﬁts are
closely balanced with harms, or that harms outweigh beneﬁts.
B. The NACB recommends adoption
Recommendations for adoption are made when
c There is moderate-quality evidence and level of agreement of experts that the intervention improves important health outcomes and that
beneﬁts outweigh harms; or
c There is low-quality evidence but strong or very strong agreement and high level of conﬁdence of experts that the intervention improves
important health outcomes and that beneﬁts outweigh harms; or
c There is very low–quality evidence but very strong agreement and very high level of conﬁdence of experts that the intervention improves
important health outcomes and that beneﬁts outweigh harms.
Recommendations against adoption are made when
c There is moderate-quality evidenceand levelof agreement of experts that theintervention is ineffective or that beneﬁts are closelybalanced
with harms, or that harms outweigh beneﬁts; or
c There is low-qualityevidencebut strongor verystrongagreement and high levelof conﬁdenceof expertsthat theintervention is ineffective
or that beneﬁts are closely balanced with harms, or that harms outweigh beneﬁts; or
c Thereisverylow–qualityevidencebutverystrongagreementandveryhighlevelsofconﬁdenceofexpertsthattheinterventionisineffective
or that beneﬁts are closely balanced with harms, or that harms outweigh beneﬁts.
C. The NACB concludes that there is insufﬁcient information to make a recommendation
Grade C is applied in the following circumstances:
c Evidenceislackingorscarceorofverylowquality,thebalanceofbeneﬁtsandharmscannotbedetermined,andthereisnoorverylowlevel
of agreement of experts for or against adoption of the recommendation.
c Atanylevelofevidence—particularlyiftheevidenceisheterogeneousorinconsistent,indirect,orinconclusive—ifthereisnoagreementof
experts for or against adoption of the recommendation.
GPP. The NACB recommends it as a good practice point
GPPsarerecommendationsmostlydrivenbyexpertconsensusandprofessionalagreementandarebasedontheinformationlistedbelowand/or
professional experience, or widely accepted standards of best practice. This category applies predominately to technical (e.g., preanalytical,
analytical, postanalytical), organizational, economic,or quality-management aspects of laboratorypractice.In thesecases,evidenceoftencomes
from observational studies, audit reports, case series or case studies, nonsystematic reviews, guidance or technical documents, non–evidence-
based guidelines, personal opinions, expert consensus, or position statements. Recommendations are often based on empirical data, usual
practice, quality requirements and standards set by professional or legislative authorities or accreditation bodies, and so forth.
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Sacks and Associates(age .25 years) with type 1 diabetes.
A( h i g h )
b. Although the evidence for lowering
HbA1c is not as strong for children, teens,
and younger adults, real-time CGM may
be helpful in these groups. Success corre-
lateswithadherencetoongoing useofthe
device. B (moderate)
c. Real-time CGM may be a supplemental
tool to SMBG in individuals with hypo-
glycemia unawareness and/or frequent
episodes of hypoglycemia. B( l o w )
d. Patients require extensive training in
using the device. Available devices must
be calibrated with SMBG readings, and
the latter are recommended for making
treatment changes. GPP
4. Noninvasive glucose analysis
a. No noninvasive sensing technology is
currently approved for clinical glucose
measurements of any kind. Major tech-
nological hurdles must be overcome be-
fore noninvasive sensing technology will
be sufﬁciently reliable to replace existing
portable meters, implantable biosensors,
or minimally invasive technologies.
C( v e r yl o w )
5. Gestational diabetes mellitus
a. All pregnant women not previously
known to have diabetes should undergo
testing for gestational diabetes mellitus
(GDM) at 24–28 weeks of gestation.
A( h i g h )
b. GDM should be diagnosed by a 75-g
oral glucose tolerance test according to
the IADPSG (International Association
of the Diabetes and Pregnancy Study
Groups) criteria derived from the HAPO
(Hyperglycemia and Adverse Pregnancy
Outcome) study. A (moderate)
6. Urinary glucose
a. Semiquantitative urine glucose testing
is not recommended for routine care of
patients with diabetes mellitus. B( l o w )
7. Ketone testing
a. Ketones measured in urine or blood in
the home setting by patients with diabetes
and in the clinic/hospital setting should be
consideredonlyanadjuncttothediagnosis
of diabetic ketoacidosis (DKA). GPP
b.Urineketonemeasurementsshouldnot
beusedtodiagnoseormonitorthecourse
of DKA. GPP
c. Blood ketone determinations that rely
on the nitroprusside reaction should be
used only as an adjunct to diagnose
D K Aa n ds h o u l dn o tb eu s e dt om o n i t o r
DKA treatment. Speciﬁc measurement of
b-hydroxybutyric acid in blood can be
used for diagnosis and monitoring of
DKA. B (moderate)
8. HbA1c
a. HbA1c should be measured routinely in
all patients with diabetes mellitus to doc-
ument their degree of glycemic control.
A (moderate)
b. Laboratories should use only HbA1c
assay methods that are certiﬁed by the
National Glycohemoglobin Standardiza-
tion Program (NGSP) as traceable to the
DCCT (Diabetes Control and Complica-
tions Trial) reference. The manufacturers
of HbA1c assays should also show trace-
ability to the IFCC reference method.
GPP
c. Laboratories that measure HbA1c
shouldparticipatein aproﬁciency-testing
program, such as the College of American
Pathologists (CAP) HbA1c survey, that
uses fresh blood samples with targets set
by the NGSP Laboratory Network. GPP
d. Laboratories should be aware of po-
tential interferences, including hemoglo-
binopathies, that may affect HbA1c test
results, depending on the method used.
In selecting assay methods, laboratories
should consider the potential for interfer-
ences in their particular patient popula-
tion. In addition, disorders that affect
erythrocyte turnover may cause spurious
results, regardless of the method used.
GPP
e. DesirablespeciﬁcationsforHbA1c mea-
surement are an intralaboratory CV ,2%
a n da ni n t e r l a b o r a t o r yC V,3.5%. At
least two control materials with different
mean values should be analyzed as an in-
dependentmeasureofassayperformance.
B( l o w )
f. Samples with HbA1c results below the
lower limit of the reference interval
or .15% HbA1c should be veriﬁed by re-
peat testing. B( l o w )
g. HbA1c values that are inconsistent with
the clinical presentation should be inves-
tigated further. GPP
h. Treatment goals should be based on
AmericanDiabetesAssociationrecommen-
dations, which include generally maintain-
ing HbA1c concentrations at ,7% and
more-stringent goals in selected individual
patients if they can be achieved without
signiﬁcant hypoglycemia or other adverse
treatment effects. Somewhat higher inter-
vals are recommended for children and
adolescentsandmaybeappropriateforpa-
tients with limited life expectancy, exten-
sive comorbid illnesses, a history of severe
hypoglycemia, or advanced complications
(notethatthesevaluesareapplicableonlyif
the NGSP has certiﬁedthe assaymethod as
traceabletotheDCCTreference).A(high)
i. HbA1c testing should be performed at
least biannually in all patients and quar-
terly for patients whose therapy has
changed or who are not meeting treat-
ment goals. B( l o w )
j. HbA1c may be used for the diagnosis of
diabetes, with values $6.5% being diag-
nostic. An NGSP-certiﬁed methodshould
be performed in an accredited laboratory.
Analogoustoitsuseinthemanagementof
diabetes, factors that interfere with or ad-
versely affect the HbA1c assay will pre-
clude its use in diagnosis. A (moderate)
k. Point-of-care HbA1c assays are not suf-
ﬁciently accurate to use for the diagnosis
of diabetes. B (moderate)
9. Genetic markers
a. Routine measurement of genetic mark-
e r si sn o to fv a l u ea tt h i st i m ef o rt h e
diagnosisor management of patientswith
type 1 diabetes. For selected diabetic syn-
dromes, including neonatal diabetes,
valuable information can be obtained
with deﬁnition of diabetes-associated mu-
tations. A( m o d e r a t e )
b. There is no role for routine genetic
testing in patients with type 2 diabetes.
These studies should be conﬁned to the
research setting and evaluation of speciﬁc
syndromes. A (moderate)
10. Autoimmune markers
a. Islet cell autoantibodies are recom-
mended for screening nondiabetic family
memberswhowishtodonatepartoftheir
pancreas for transplantation into a relative
with end-stage type 1 diabetes. B( l o w )
b. Islet cell autoantibodies are not recom-
mendedforroutinediagnosisofdiabetes,
but standardized islet cell autoantibody
tests may be used for classiﬁcation of
diabetes in adults and in prospective
studies of children at genetic risk for
type 1 diabetes after HLA typing at birth.
B( l o w )
c. Screening patients with type 2 diabetes
for islet cell autoantibodies is not recom-
mended at present. Standardized islet cell
autoantibodies are tested in prospective
clinical studies of type 2 diabetic patients
to identify possible mechanisms of sec-
ondary failures of treatment of type 2
diabetes. B( l o w )
d. Screening for islet cell autoantibodies
in relatives of patients with type 1 di-
abetes or in persons from the general
population is not recommended at pres-
ent. Standardized islet cellautoantibodies
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B( l o w )
e. There is currently no role for measure-
ment of islet cell autoantibodies in the
monitoringofpatientsinclinicalpractice.
Islet cell autoantibodies are measured in
research protocols and in some clinical
trials as surrogate end points. B( l o w )
f. It is important that islet cell autoanti-
bodies be measured only in an accredited
laboratory with an established quality-
control program and participation in a
proﬁciency-testing program. GPP
11. Albuminuria (formerly
microalbuminuria)
a. Annual testing for albuminuria in pa-
tients without clinical proteinuria should
begin in pubertal or postpubertal indi-
viduals 5 years after diagnosis of type 1
diabetes and at the time of diagnosis
oftype2diabetes,regardlessoftreatment.
B (moderate)
b. Urine albumin at concentrations $30
mg/g creatinine should be considered as a
continuousriskmarkerforcardiovascular
events. B (moderate)
c. The analytical CV of methods to mea-
sure albuminuria should be ,15%.
B (moderate)
d. Semiquantitative or qualitative screen-
ing tests should be positive in .95% of
patients with albuminuria to be useful for
screening. Positive results must be con-
ﬁrmed by analysis in an accredited labo-
ratory. GPP
e.Currentlyavailabledipsticktestsdonot
have adequate analytical sensitivity to
detect albuminuria. B( m o d e r a t e )
f. Acceptable samples to test for increased
urinary albumin excretion are timed collec-
ti o ns( e. g. ,1 2or2 4h)f o rtheme asur ement
of albumin concentration and timed or
untimed samples for measurement of the
albumin–creatinine ratio. B (moderate)
g. The optimal time for spot urine collec-
tion is the early morning. All collections
should be at the same time of day to min-
imize variation. The patient should not
have ingested food within the preceding
2 h, but should be well hydrated (i.e., not
volume depleted). GPP
h. Low urine albumin concentrations
(i.e., ,30 mg/g creatinine) are not associ-
ated with high cardiovascular risk if the
estimated glomerular ﬁltration rate (eGFR)
is .60 mL z min
21 z (1.73 m
2)
21 and
the patient is normotensive. If the eGFR
is ,60 mL z min
21 z (1.73 m
2)
21 and/or
the level of albuminuria is $30 mg/g cre-
atinine on a spot urine sample, a repeat
measurement should be taken within the
year to assess change among people with
hypertension. A (moderate)
12. Miscellaneous potentially
important analytes
a. There is no role for routine testing for
insulin, C-peptide, or proinsulin in most
patients with diabetes. Differentiation be-
tween type 1 and type 2 diabetes may be
made in most cases on the basis of the
clinical presentation and the subsequent
course. These assays are useful primarily
for research purposes. Occasionally, C-
peptide measurements may help distin-
guish type 1 from type 2 diabetes in
ambiguous cases, such as patients who
have a type 2 phenotype but present in
ketoacidosis. B (moderate)
b. There is no role for measurement of
insulinconcentrationintheassessmentof
cardiometabolic risk, because knowledge
of this value does not alter the manage-
ment of these patients. B (moderate)
c. Because current measures of insulin are
poorly harmonized, a standardized insu-
lin assay should be developed to encour-
age the development of measures of
insulin sensitivity that will be practical
for clinical care. GPP
d. There is no published evidence to
support the use of insulin antibody test-
ing for routine care of patients with di-
abetes. C( v e r yl o w )
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